Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation
Sponsored by University Hospital, Caen
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Started a year ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Males and females, age at least 18 years, in ESRD threated with peritoneal dialysis for ≥ 3 months
- Patients with a history of non valvular AF treated by oral anticoagulation or patients initiating oral anticoagulation for a diagnosis of non valvular AF
- CHA2DS2-VASc score of ≥ 2.
Exclusion Criteria
- Not considered by the treating physician(s) to be candidates for oral anticoagulation (for example, hemoglobin <8.5g/dL, history of intracranial hemorrhage, active bleeding, recent gastrointestinal bleed or retroperitoneal bleed, severe hepatic impairment, or anaphylactic reaction to apixaban) • Moderate or severe mitral stenosis
- Conditions other than non valvular AF that require anticoagulation such as mechanical prosthetic valve, deep venous thrombosis, or pulmonary embolism
- Life expectancy < 3 months
- Anticipated kidney transplant within the next 3 months
- childbearing potential